In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just a few months later, the Pfizer ...
With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
A new chapter is unfolding for gene therapies in Europe. With retinal programs advancing into Phase I/II trials and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results